Capecitabine doses were reduced by 50% for patients who experienced a third occurrence of a given grade 2 event, a second occurrence of a given grade 3 event, or any grade 4 event.
Capecitabine doses were reduced by 50% to 500 mg m−2 twice daily for patients who experienced a third occurrence of a given grade 2 event, a second occurrence of a given grade 3 event, or any grade 4 event.
If patients experienced a third occurrence of a given grade 2 toxicity, a second occurrence of a given grade 3 toxicity, or any grade 4 toxicity, both doses were reduced by 40%.
Capecitabine doses were reduced by 20% for patients who experienced a first occurrence of a grade 3 haematological toxicity, a second occurrence of grade 2 non-haematological toxicity or any grade 3 non-haematological toxicity.
A Cox model was used to identify the correlates of a first occurrence of a major CADE.
If patients experienced a third occurrence of a given Grade 2 toxicity or a second occurrence of a given Grade 3 toxicity, treatment was interrupted/delayed until the toxicity resolved to Grades 0 1 and the dose of capecitabine was reduced by 50% and paclitaxel discontinued.
When treatment was resumed, capecitabine doses were reduced as follows: by 25% (1000 mg) for patients who experienced a second occurrence of a given grade 2 nonhaematological toxicity, or a first occurrence of a haematological toxicity or any grade 3 toxicity; or by 50% (2000 mg) for patients who experienced a grade 3 haematological toxicity.
Treatment in these patients was discontinued in the event of a fourth occurrence of a grade 3 reaction.
Treatment with both agents was interrupted/delayed and the dose of both agents was reduced by 25% in patients who experienced a second occurrence of a given Grade 2 toxicity or at the first occurrence of a Grade 3 toxicity.
Capecitabine dose was reduced by 25% for patients who experienced a second occurrence of a given grade 2 event or any grade 3 event.
The doses of docetaxel and oxaliplatin were reduced by 20% in patients who experienced a second occurrence of a given grade 2 toxicity or any grade 3 toxicity.
